risk

Aon’s 2025 Global Cyber Risk Report Reveals Reputation Risk Events Can Reduce Shareholder Value by 27 percent

DUBLIN, June 17, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today released its 2025 Cyber…

7 months ago

XRP price: Massive sell-off forces holders to flock to EarnMining for stable income

Houston, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- After experiencing a short-term price plunge, the XRP market has set off…

7 months ago

MEXC Unveils “Proof of Trust” Campaign for Crypto Security, Audits, and User Protection

VICTORIA, Seychelles, June 16, 2025 /PRNewswire/ -- MEXC, a leading global cryptocurrency exchange, has launched Proof of Trust, a comprehensive…

7 months ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

7 months ago

Zero Trust Security Reduces Cyber Insurance Claims, Preventing up to $465 Billion Annually in Global Economic Loss from Cyber Attacks

Nearly a third of the cyber events encompassed by the study potentially could have been prevented if zero trust was…

7 months ago

SEON Launches AI-Powered Anti-Money Laundering Suite, Enhancing its Comprehensive Command Center for Risk Management

AUSTIN, Texas, June 10, 2025 (GLOBE NEWSWIRE) -- SEON, a global leader in digital fraud prevention, announced the launch of…

7 months ago

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

7 months ago

Aon appoints Andy Marcell to serve as CEO of Global Solutions

DUBLIN, June 2, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, announced today that the firm…

7 months ago

Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p

7 months ago

AI Meets Audit Powerhouse: Qualifyze Launches Quality Insights Platform to Help Global Pharma Manage Supplier Site Risk

FRANKFURT, Germany, May 29, 2025 /PRNewswire/ -- Qualifyze, already the global leader in third-party audit services for the pharmaceutical industry,…

8 months ago